
Acadia Pharmaceuticals shows steady growth with Nuplazid and Daybue, eyes high-risk Alzheimer's drug catalyst.
Acadia Pharmaceuticals continues steady commercial growth driven by its products Nuplazid and Daybue, supported by a positive CHMP opinion for Daybue in Europe. The company’s upcoming phase 2 trial results for remimfanserin in Alzheimer's disease psy...

